Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. InnoCare Pharma's EBITDA for the
six
months ended in Dec. 2025 was €93.7 Mil. InnoCare Pharma's Revenue for the
six
months ended in Dec. 2025 was €199.3 Mil. Therefore, InnoCare Pharma's EBITDA margin for the quarter that ended in Dec. 2025 was 47.01%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
InnoCare Pharma EBITDA Margin % Related Terms
InnoCare Pharma EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for InnoCare Pharma's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:33C vs VRTX, REGN, RVMD: EBITDA Margin % Comparison
For the Biotechnology subindustry, InnoCare Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InnoCare Pharma EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, InnoCare Pharma's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where InnoCare Pharma's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InnoCare Pharma (STU:33C) has a EBITDA Margin % of 47.01% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on InnoCare Pharma and its competitors. According to the industry distribution chart, InnoCare Pharma ranks #97 out of 942 companies in the Biotechnology industry, placing it in the top 10.3%.
Is InnoCare Pharma's EBITDA Margin % too high?
InnoCare Pharma's current EBITDA Margin % is 47.01%. Based on the distribution chart, InnoCare Pharma ranks #97 out of 942 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, InnoCare Pharma has a GF Score™ of 78/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCare Pharma's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, InnoCare Pharma ranks #97 out of 942 companies for EBITDA Margin %. This places InnoCare Pharma in the top 10% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on InnoCare Pharma and its competitors. InnoCare Pharma's current EBITDA Margin % is 47.01%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCare Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCare Pharma (STU:33C) is currently considered Possible Value Trap. The stock's GF Value™ is €2.29, compared to a current price of €1.51 — trading 34.1% below its estimated fair value. The current EBITDA Margin % is 47.01%. InnoCare Pharma's overall GF Score™ is 78/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For InnoCare Pharma (STU:33C), the current EBITDA Margin % is 47.01% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InnoCare Pharma (STU:33C) Overvalued in 2026?
Based on GuruFocus' analysis, InnoCare Pharma stock appears to be undervalued.
The current stock price of €1.51 is trading 34.1% below its estimated GF Value™ of €2.29.
GuruFocus considers InnoCare Pharma to be Possible Value Trap.
Key valuation signals for STU:33C:
EBITDA Margin %: 47.01%
GF Value™: €2.29 vs. price of €1.51 (34.1% below fair value)
No single metric tells the full story. See the STU:33C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.
78GF Score
Get the complete analysis for STU:33C
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:33C has been successfully added to your 
